At YongLin Foundation, we believe that no one should face cancer without access to the world’s best care—and that compassion should move as fast as science. Our commitment is simple yet bold: to transform the way cancer is understood, treated, and ultimately defeated. We’re not just treating illness—we’re building hope, one breakthrough at a time.
Completed in 2018 after a decade of meticulous planning, NTUCC is Taiwan’s first public cancer hospital built through private philanthropy. It stands as a living legacy of YongLin Foundation founder Terry Gou, who transformed personal grief into a national gift of hope. NTUCC is more than a hospital—it is a beacon of what compassionate innovation can achieve.
Radiotherapy reaches new heights in the YongLin Building, where we launched photon therapy in 2022 and are preparing to introduce precision-guided proton therapy. These treatments offer unparalleled accuracy, preserving healthy tissue while aggressively targeting tumors—a game changer for patients in Taiwan and across the region.
NTUCC is the foundation of a far-reaching vision: to make Taiwan a global leader in biomedical innovation. This future-forward initiative is designed not only to cure disease but to prevent it—putting Taiwan on the map as Asia’s model for next-generation healthcare.
In collaboration with National Taiwan University, we created the first breast cancer gene database tailored specifically for Chinese populations. This powerful resource enables researchers to decode the genetic origins of cancer and develop personalized treatments faster and more effectively than ever before.
Backed by our historic NT$20 billion donation to NTU, the Tai-Chen Cell Therapy Center is Taiwan’s largest and most advanced facility of its kind. It delivers life-saving hematopoietic stem cell transplants for patients with leukemia, lymphoma, and other severe blood disorders—ushering in a new chapter of regenerative medicine and individualized care.
